A study of 124 diabetes patients showed that rosiglitazone reduced the risk of developing proliferative diabetic retinopathy or deterioration of visual acuity by curbing the formation of new blood vessels. Researchers, however, said larger studies need to be conducted before they can recommend the drug to treat the condition.

Related Summaries